clinical trial · NCT04602754
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
EMS·phase3·recruiting·n = 228
Dyslipidemia Associated With Type II Diabetes MellitusBERLIM 25/20 ASSOCIATIONEMPAGLIFLOZIN PLACEBOROSUVASTATIN CALCIUM PLACEBOEMPAGLIFLOZINROSUVASTATIN CALCIUMBERLIM 25/20 ASSOCIATION PLACEBO
brief summary
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
started
Dec 1, 2023
primary completion
May 1, 2026
completion
Sep 1, 2027
last updated
Dec 8, 2025
official title
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol